Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Catalent 3rd Quarter Results | Contract Pharma

What are you searching for?

Sign in
Breaking News, Financial News

Catalent 3rd Quarter Results

Revenues down 19% to $1.04 billion, while costs associated with Consumer Health unit contribute to loss of $227 million in the quarter.

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

Catalent
3Q Revenues: $1.04 billion (-19%)
3Q Loss: $227 million (earnings were $141 million 3Q22)
Comments: Biologics revenue was $475 million in the quarter, down 32%. Pharma and Consumer Health revenues were $563 million, down 2%. Loss in the quarter includes a goodwill impairment of $210 million associated with the company’s Consumer Health reporting unit. Unallocated costs in the quarter were $256 million, compared to $54 million in 3Q22. Restructuring costs in the quarter and December 31, 2022 represent restructuring charges associated with Catalent’s plans to reduce costs, consolidate facilities, and optimize its infrastructure across the organization. Acquisition, integration and other special items during the three months ended December 31, 2022 include costs associated with its October 2022 acquisition of Metrics Contract Services.

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters